Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 4
2006 2
2007 4
2008 2
2009 2
2010 3
2011 3
2012 1
2013 2
2014 1
2015 4
2016 4
2017 8
2018 3
2019 4
2020 6
2021 10
2022 6
2023 6
2024 13
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

78 results

Results by year

Filters applied: . Clear all
Page 1
Traitements personnalisés grâce à la pharmacogénétique : niveaux de preuve et de recommandations du Réseau national de pharmacogénétique (RNPGx).
Picard N, Boyer JC, Etienne-Grimaldi MC, Barin-Le Guellec C, Thomas F, Loriot MA; Réseau national de pharmacogénétique (RNPGx). Picard N, et al. Among authors: thomas f. Therapie. 2017 Apr;72(2):175-183. doi: 10.1016/j.therap.2016.09.007. Epub 2017 Jan 3. Therapie. 2017. PMID: 28153355 French. No abstract available.
Influence of DPYD gene polymorphisms on 5-Fluorouracil toxicities in Thai colorectal cancer patients.
Atasilp C, Vanwong N, Yodwongjane P, Chansriwong P, Sirachainan E, Reungwetwattana T, Jinda P, Aiempradit S, Sirilerttrakul S, Chamnanphon M, Puangpetch A, Sankuntaw N, Satapornpong P, Fabienne T, Sukasem C. Atasilp C, et al. Among authors: fabienne t. Cancer Chemother Pharmacol. 2024 Dec 9;95(1):2. doi: 10.1007/s00280-024-04722-z. Cancer Chemother Pharmacol. 2024. PMID: 39652193 Free PMC article.
Metabolic reprogramming of hypoxic tumor-associated macrophages through CSF-1R targeting favors treatment efficiency in colorectal cancers.
Gharzeddine K, Gonzalez Prieto C, Malier M, Hennot C, Grespan R, Yamaryo-Botté Y, Botté CY, Thomas F, Laverriere MH, Girard E, Roth G, Millet A. Gharzeddine K, et al. Among authors: thomas f. J Immunother Cancer. 2024 Sep 24;12(9):e009602. doi: 10.1136/jitc-2024-009602. J Immunother Cancer. 2024. PMID: 39317456 Free PMC article.
Dihydropyrimidine dehydrogenase gene variants for predicting grade 4-5 fluoropyrimidine-induced toxicity: FUSAFE individual patient data meta-analysis.
Le Teuff G, Cozic N, Boyer JC, Boige V, Diasio RB, Taieb J, Meulendijks D, Palles C, Schwab M, Deenen M, Largiadèr CR, Marinaki A, Jennings BA, Wettergren Y, Di Paolo A, Gross E, Budai B, Ackland SP, van Kuilenburg ABP, McLeod HL, Milano G, Thomas F, Loriot MA, Kerr D, Schellens JHM, Laurent-Puig P, Shi Q, Pignon JP, Etienne-Grimaldi MC; FUSAFE collaborative group. Le Teuff G, et al. Among authors: thomas f. Br J Cancer. 2024 Mar;130(5):808-818. doi: 10.1038/s41416-023-02517-2. Epub 2024 Jan 15. Br J Cancer. 2024. PMID: 38225422 Free PMC article.
Nonlinear Mixed-Effects Model of Z-Endoxifen Concentrations in Tamoxifen-Treated Patients from the CEPAM Cohort.
Mc Laughlin AM, Helland T, Klima F, Koolen SLW, van Schaik RHN, Mathijssen RHJ, Neven P, Swen JJ, Guchelaar HJ, Dalenc F, White-Koning M, Michelet R, Mikus G, Schroth W, Mürdter T, Brauch H, Schwab M, Søiland H, Mellgren G, Thomas F, Kloft C, Hertz DL; CYP2D6 Endoxifen Percentage Activity Model (CEPAM) Consortium. Mc Laughlin AM, et al. Among authors: thomas f. Clin Pharmacol Ther. 2024 Sep;116(3):690-702. doi: 10.1002/cpt.3238. Epub 2024 Mar 18. Clin Pharmacol Ther. 2024. PMID: 38494911
Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiency.
Etienne-Grimaldi MC, Pallet N, Boige V, Ciccolini J, Chouchana L, Barin-Le Guellec C, Zaanan A, Narjoz C, Taieb J, Thomas F, Loriot MA; Francophone Network of Pharmacogenetics (RNPGx) and the French Clinical Oncopharmacology Group (GPCO)-UNICANCER. Etienne-Grimaldi MC, et al. Among authors: thomas f. Eur J Cancer. 2023 Mar;181:3-17. doi: 10.1016/j.ejca.2022.11.028. Epub 2022 Dec 9. Eur J Cancer. 2023. PMID: 36621118 Review.
Ototoxicity of high-dose carboplatin.
Chevreau C, Thomas F, Couteau C, Dalenc F, Mourey L, Chatelut E. Chevreau C, et al. Among authors: thomas f. J Clin Oncol. 2005 May 20;23(15):3649-50; author reply 3650-1. doi: 10.1200/JCO.2005.05.348. J Clin Oncol. 2005. PMID: 15908692 No abstract available.
78 results